ERBB2 and cancer: For example, the benefit of zolbetuximab in combination with chemotherapy was observed in cancers with moderate or strong expression of the target claudin 18.2 in more than 75% of tumor cells, and HER2-targeted therapies are of benefit in cancers with at least some degree of expression of the target receptor [5,7].